Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Vicore Pharma Holding AB ( (SE:VICO) ) is now available.
Vicore Pharma announced its participation in the Jefferies Global Healthcare Conference in London, where key executives will present and engage in one-on-one meetings. This event provides an opportunity for Vicore to showcase its innovative drug programs and strengthen its industry presence, potentially impacting its market positioning and stakeholder engagement.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing a novel class of drugs, particularly angiotensin II type 2 receptor agonists (ATRAGs), with potential applications in respiratory and fibrotic diseases such as idiopathic pulmonary fibrosis (IPF). Their lead program, buloxibutid, is an oral small molecule that has received Orphan Drug and Fast Track designation from the FDA and is currently in a Phase 2b trial.
YTD Price Performance: 17.87%
Average Trading Volume: 665,045
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.34B
See more insights into VICO stock on TipRanks’ Stock Analysis page.